Quarterly ResultMay 7, 2026, 07:12 AM
Beam Therapeutics Q1 Net Loss $94.3M; Cash Runway into mid-2029
AI Summary
Beam Therapeutics reported first quarter 2026 financial results, with a net loss of $94.3 million, an improvement from $108.3 million in Q1 2025, and a significant increase in license and collaboration revenue to $31.7 million. The company ended the quarter with $1.2 billion in cash, cash equivalents, and marketable securities, extending its cash runway into mid-2029. Key business updates include strong topline data for BEAM-302 in AATD, with a pivotal cohort expected to start in H2 2026, and anticipated BLA submission for Risto-cel in Sickle Cell Disease as early as year-end 2026.
Key Highlights
- Q1 2026 Net Loss: $94.3 million, improved from $108.3 million in Q1 2025.
- Q1 2026 Revenue: $31.7 million, up from $7.5 million in Q1 2025.
- Cash, cash equivalents, and marketable securities: $1.2 billion as of March 31, 2026.
- Cash runway: Expected to support operating plans into mid-2029.
- BEAM-302: Pivotal cohort for AATD expected to initiate in H2 2026.
- Risto-cel: BLA submission for Sickle Cell Disease expected as early as year-end 2026.
- BEAM-304: IND application for PKU anticipated in 2026.
- R&D expenses: $104.5 million in Q1 2026, up from $98.8 million in Q1 2025.